We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.57B
AUM Growth
+$29.7M
Cap. Flow
-$123M
Cap. Flow %
-7.84%
Top 10 Hldgs %
52.92%
Holding
277
New
83
Increased
54
Reduced
60
Closed
62

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.2M
2
MNKD icon
MannKind Corp
MNKD
+$15.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$4.32M
4
TWTR
Twitter, Inc.
TWTR
+$3.59M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.08M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.5M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$10.9M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
AGEN
Agenus
AGEN
+$4.63M
5
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 9.13%
2 Communication Services 0.29%
3 Materials 0.04%
4 Financials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
226
Celldex Therapeutics
CLDX
$2.79B
– –
-2,132
Closed -$821K
EWA icon
227
PUT
iShares MSCI Australia ETF
EWA
$1.39B
– –
-50,000
Closed -$59.5M
EWJ icon
228
iShares MSCI Japan ETF
EWJ
$21.3B
– –
-6,250
Closed -$298K
FBIO icon
229
CALL
Fortress Biotech
FBIO
$113M
– –
-71
Closed -$748K
FBIO icon
230
PUT
Fortress Biotech
FBIO
$113M
– –
-29
Closed -$304K
GERN icon
231
CALL
Geron
GERN
$930M
– –
-1,187
Closed -$376K
GERN icon
232
PUT
Geron
GERN
$930M
– –
-2,201
Closed -$697K
HOLX
233
CALL
DELISTED
Hologic
HOLX
– –
-1,110
Closed -$2.29M
MDGL icon
234
CALL
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-36
Closed -$791K
MDGL icon
235
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-7,170
Closed -$1.58M
MDGL icon
236
PUT
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-85
Closed -$1.89M
MRK icon
237
PUT
Merck
MRK
$326B
– –
-307
Closed -$1.4M
NBIX icon
238
Neurocrine Biosciences
NBIX
$18.4B
– –
-218,849
Closed -$2.14M
NKTR icon
239
CALL
Nektar Therapeutics
NKTR
$2.39B
– –
-44
Closed -$686K
PBF icon
240
CALL
PBF Energy
PBF
$7.22B
– –
-1,995
Closed -$4.48M
SVRA icon
241
Savara
SVRA
$1.09B
– –
-51,994
Closed -$1.6M
TENX icon
242
Tenax Therapeutics
TENX
$419M
– –
-1
Closed -$54K
TMP icon
243
Tompkins Financial
TMP
$1.45B
– –
-288,454
Closed -$1.02M
UTHR icon
244
CALL
United Therapeutics
UTHR
$26.1B
– –
-168
Closed -$1.32M
VCEL icon
245
Vericel Corp
VCEL
$2.39B
– –
-259,461
Closed -$1.44M
VNDA icon
246
CALL
Vanda Pharmaceuticals
VNDA
$310M
– –
-1,827
Closed -$2M
VNDA icon
247
PUT
Vanda Pharmaceuticals
VNDA
$310M
– –
-1,515
Closed -$1.66M
VRTX icon
248
Vertex Pharmaceuticals
VRTX
$124B
– –
-336,955
Closed -$23.5M
XOMA
249
PUT
DELISTED
Xoma
XOMA
– –
-83
Closed -$742K
IRD
250
Opus Genetics
IRD
$282M
– –
-4,689
Closed -$1.01M
8 9
10
11 12

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2013 Portfolio in Review

As of Q4 2013, Sabby Management held 277 positions worth $1.57B, up 1.9% from $1.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $123M in Q4 2013, closing 62 positions and reducing 60 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.1% of assets, down from 10% a quarter earlier, followed by Communication Services and Materials.

Against the trend, Sabby Management opened a new position in Arbutus Biopharma worth $4.14M.

  • Sabby Management's largest Q4 2013 buy was Arbutus Biopharma: 519,200 shares worth $4.14M.
  • Sabby Management added most to Teva Pharmaceuticals in Q4 2013, an estimated $17.2M increase.
  • Sabby Management's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $10.9M.
  • Sabby Management fully exited Vertex Pharmaceuticals in Q4 2013, selling an estimated $23.5M.
  • Sabby Management's ten largest holdings make up 53% of its $1.57B portfolio in Q4 2013.
  • Sabby Management opened 83 new positions and closed 62 in Q4 2013.
  • Sabby Management's portfolio value rose 1.9% quarter-over-quarter to $1.57B.

Based on Sabby Management's 13F filing for Q4 2013, filed 14 Feb 2014.